# ALPHAROSE THERAPEUTICS INC.: Anti-Sense Oligonucleotide Therapy for HNRNPH2 Neurodevelopmental Disorder.

**Lab Budget Score:** 40/100

| Field | Value |
|---|---|
| Organization | ALPHAROSE THERAPEUTICS INC. |
| Location | Leander, TX |
| Project | Anti-Sense Oligonucleotide Therapy for HNRNPH2 Neurodevelopmental Disorder. |
| Project number | 1R44HD122555-01 |
| Mechanism | R44 |
| Institute | Eunice Kennedy Shriver National Institute of Child Health and Human Development |
| Award | $313,208 |
| Awarded | 2026-09-17 |
| Project period | 2026-09-20 to 2027-08-31 |
| UEI | NEAQXBDXKMD7 |

## Why this score
- Award of $313,208.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11408035). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.